Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CENPE | Q02224 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617280 | 0.89 | GAA (0.47) | GAACENPENPC1RAB9AALDH1A1 | |
| SCHEMBL14531324 | 0.87 | NPC1 (0.47) | GAACENPENPC1RAB9AALDH1A1 | |
| SCHEMBL2617281 | 0.84 | GAA (0.45) | GAACENPENPC1RAB9AALDH1A1 | |
| SCHEMBL14449510 | 0.80 | POLB (0.52) | CENPERAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13162181 | 0.78 | CENPE (0.62) | CENPEHPGDCA1CA2CSNK2A1 | |
| SCHEMBL2617156 | 0.78 | CENPE (0.79) | CENPETP53CSNK2A1KMT2A | |
| SCHEMBL4720774 | 0.78 | CENPE (0.47) | CENPERAB9AALDH1A1TSHRPOLB | |
| SCHEMBL2617121 | 0.78 | CENPE (0.79) | CENPETP53CSNK2A1KMT2A | |
| SCHEMBL2617277 | 0.77 | KIFC1 (0.41) | GAACENPENPC1RAB9AGCGR | |
| SCHEMBL2104606 | 0.77 | CENPE (0.48) | CENPEALDH1A1TSHRCSNK2A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | GAA 466/4885CENPE 54/4885NPC1 835/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | GAA 466/4885CENPE 54/4885NPC1 835/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | GAA 466/4885CENPE 54/4885NPC1 835/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | GAA 395/4885CENPE 50/4885NPC1 619/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | GAA 466/4885CENPE 54/4885NPC1 835/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | GAA 466/4885CENPE 54/4885NPC1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.